ArticleBMC cardiovascular disorders2026
Multi-omics analysis of human right atrial tissue ıdentifies molecular signatures of remodeling in tricuspid regurgitation.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricuspid regurgitation (TR) is associated with adverse clinical outcomes, yet the underlying right atrial (RA) molecular remodeling remains poorly understood. We aimed to define TR-associated RA remodeling using metabolomic and lipidomic profiling of human RA tissue.
methodsRA appendage tissue was obtained intraoperatively from 24 adults undergoing cardiac surgery (11 with ≥severe TR; 13 controls). Gas chromatography mass spectrometry (GC-MS) was used for targeted small-molecule metabolomics, and liquid chromatography quadrupole time of flight mass spectrometry (LC-qTOF-MS) for untargeted lipidomics. Mann Whitney U testing, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and variable importance in projection (VIP) scoring were used to identify discriminatory multi-omics patterns between groups.
resultsPatients with TR demonstrated a distinct metabolic phenotype characterized by reduced glycolysis-related intermediates (glucose-6-phosphate, β-alanine, α-glucosamine-1-phosphate; all p < 0.05) and metabolites consistent with oxidative stress and amino acid catabolism markers (6-hydroxycaproic acid, porphine, phosphoric acid; all p < 0.05). Lipidomic analysis revealed broad phospholipid remodeling and signals consistent with mitochondrial-associated alterations, including a decreased phosphatidylcholine/phosphatidylethanolamine (PC/PE) ratio and reductions in selected diacylglycerol and ceramide species. PCA and PLS-DA demonstrated clear group separation with consistent VIP signals, indicating consistent multi-omics discrimination.
conclusionsTR is associated with coordinated metabolic and lipidomic reprogramming in the RA, a pattern compatible with, though not direct evidence of, mitochondrial stress, impaired bioenergetics, and membrane destabilization. These findings support a model in which RA remodeling is tightly linked to TR pathophysiology, highlighting candidate molecular features for future validation. Multi-omics biomarkers may enhance risk stratification, inform the timing of intervention, and guide the development of future point-of-care molecular diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.